Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC)

Nephrology Dialysis Transplantation

Volumn 27, Issue 1, 2012, Pages 197-205

  Fung, Maple M ^a,b   Salem, Rany M ^a,b,c,d   Lipkowitz, Michael S ^e   Bhatnagar, Vibha ^a,b   Pandey, Braj ^a,b   Schork, Nicholas J ^f   O'Connor, Daniel T ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

AASK; glomerular filtration rate; hypertension; kidney disease; MTHFR

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2) GENE; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DETERIORATION; DISEASE ASSOCIATION; FEMALE; FUNCTIONAL GENOMICS; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM BY TIME INTERACTION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; DNA; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HAPLOTYPES; HUMANS; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEPHROSCLEROSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84856638074     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr257     Document Type: Article

References (66)

1. van der Put NM, Steegers-Theunissen RP, Frosst P et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346: 1070-1071
2. Goyette P, Frosst P, Rosenblatt DS et al. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995; 56: 1052-1059
3. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiolog-ical studies. J Thromb Haemost 2005; 3: 292-299 (Pubitemid 41623617)
4. Homocysteine Studies Collaboration. Homocysteine and risk of is-chemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015-2022
5. Boushey CJ, Beresford SA, Omenn GS et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057
6. Martin YN, Salavaggione OE, Eckloff BW et al. Human methylene- tetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. Pharmacogenet Genomics 2006; 16: 265-277
7. Fletcher O, Kessling AM. MTHFR association with arteriosclerotic vascular disease? Hum Genet. 1998; 103: 11-21 (Pubitemid 28398379)
8. van der Put NM, Gabreels F, Stevens EM et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet. 1998; 62: 1044-1051 (Pubitemid 28199004)
9. Pereira P, Stanton V, Jothy S et al. Loss of heterozygosity of meth-ylenetetrahydrofolate reductase in colon carcinomas. Oncol Rep 1999; 6: 597-599
10. Campbell IG, Baxter SW, Eccles DM et al. Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. Breast Cancer Res 2002; 4: R14
11. Khandanpour N, Willis G, Meyer FJ et al. Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: A case-control study and meta-analysis. J Vasc Surg. 2009; 49: 711-718
12. Morita H, Taguchi J, Kurihara H et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997; 95: 2032-2036 (Pubitemid 27184270)
13. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arterio-sclerotic outcomes. Kidney Int 1997; 52: 10-20 (Pubitemid 27321809)
14. Shishehbor MH, Oliveira LP, Lauer MS et al. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. Am J Cardiol 2008; 101: 1741-1746
15. Haviv YS, Shpichinetsky V, Goldschmidt N et al. The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients. Nephron 2002; 92: 120-126 (Pubitemid 34983885)
16. Poduri A, Mukherjee D, Sud K et al. MTHFR A1298C polymorphism is associated with cardiovascular risk in end stage renal disease in North Indians. Mol Cell Biochem 2008; 308: 43-50 (Pubitemid 351167843)
17. Sun J, Xu Y, Zhu Y et al. Genetic polymorphism of methylenetetra- hydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Res Clin Pract 2004; 64: 185-190 (Pubitemid 38582010)
18. Moczulski D, Fojcik H, Zukowska-Szczechowska E et al. Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrol Dial Transplant 2003; 18: 1535-1540 (Pubitemid 36939625)
19. Wright JT Jr, Kusek JW, Toto RD et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996; 17 (4 Suppl): 3S-16S (Pubitemid 26343150)
20. Salem RM, Pandey B, Richard E et al. Electronic medical records in the post-genomic era: The VA Hypertension Primary Care Longitudinal Cohort. Health Informatics J 2010; 16: 274-286
21. Sika M, Lewis J, Douglas J et al. Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study. Am J Kidney Dis 2007; 50: 78-89, 89 e71
22. Wright JT Jr, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431 (Pubitemid 35340538)
23. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodi-pine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719-2728 (Pubitemid 32525368)
24. Hall WD, Kusek JW, Kirk KA et al. Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study. Am J Kidney Dis 1997; 29: 720-728 (Pubitemid 27209674)
25. Gassman JJ, Greene T, Wright JT Jr et al. Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol 2003; 14 (7 Suppl 2): S154-S165 (Pubitemid 36750512)
26. Fogo A, Breyer JA, Smith MC et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int 1997; 51: 244-252 (Pubitemid 27064543)
27. Fung MM, Chen Y, Lipkowitz MS et al. Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. Nephrol Dial Transplant 2009; 24: 3677-3686
28. Brown SH, Lincoln MJ, Groen PJ et al. VistA-U.S. Department of Veterans Affairs national-scale HIS. Int J Med Inform 2003; 69: 135-156 (Pubitemid 38373274)
29. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470 (Pubitemid 29135798)
30. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. Am J Kidney Dis 2009; 53 (3 Suppl 3): S4-S16
31. Cheng S, Grow MA, Pallaud C et al. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 1999; 9: 936-949 (Pubitemid 29525202)
32. Hill W. Estimation of linkage disequilibrium in randomly mating populations. Heredity. 1974; 33: 229-239
33. Halperin E, Eskin E. Haplotype reconstruction from genotype data using imperfect phylogeny. Bioinformatics 2004; 20: 1842-1849 (Pubitemid 39199048)
34. Littell RC, Milliken GA, Stroup WW et al. SAS for Mixed Models. 2nd edn. Cary, NC: SAS Institute, Inc., 2006
35. Holden JE, Kelley K, Agarwal R. Analyzing change: a primer on multilevel models with applications to nephrology. Am J Nephrol 2008; 28: 792-801
36. Littell RC, Pendergast J, Natarajan R. Modelling covariance structure in the analysis of repeated measures data. Stat Med 2000; 19: 1793-1819 (Pubitemid 30436064)
37. Wolfinger RD. An example of using mixed models and PROC MIXED for longitudinal data. J Biopharm Stat 1997; 7: 481-500 (Pubitemid 27502170)
38. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics 2000; 1: 465-480 (Pubitemid 33213549)
39. Guo Xu, Carlin BP. Separate and joint modeling of longitudinal and event time data using standard computer packages. Am Statistician 2004; 58: 16-24 (Pubitemid 38260325)
40. Denison DGT, Mallick BK, Smith AFM. Bayesian MARS. Stat Com-put 1998; V8: 337-346
41. Faul F, Erdfelder E, Lang AG et al. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39: 175-191
42. Tripathi G, Sankhwar SN, Sharma RK et al. Role of thrombotic risk factors in end-stage renal disease. Clin Appl Thromb Hemost 2010; 16: 132-140
43. Koupepidou P, Deltas C, Christofides TC et al. The MTHFR 677TT and 677CT/1298AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure. Int Angiol 2005; 24: 287-294 (Pubitemid 41582339)
44. Neugebauer S, Baba T, Watanabe T. Methylenetetrahydrofolate re-ductase gene polymorphism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 1998; 352: 454 (Pubitemid 28362798)
45. Noiri E, Taguchi J, Nakao A, Fujita T. MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes. Analysis in Japanese male hemodialysis patients. Diabetes Care 2000; 23: 260 (Pubitemid 30071039)
46. Pernod G, Bosson JL, Golshayan D et al. Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort. Kidney Int 2006; 69: 1424-1430
47. Ibrahim S, El Dessokiy O. Prevalence of methylenetetrahydrofolate gene (MTHFR) C677T polymorphism among chronic hemodialysis patients and its association with cardiovascular disease: a cross-sectional analysis. Clin Exp Nephrol 2009; 13: 501-507
48. Kolling K, Ndrepepa G, Koch W et al. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homo-cysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. Am J Cardiol 2004; 93: 1201-1206 (Pubitemid 38595670)
49. Newton-Cheh C, Johnson T, Gateva V et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009; 41: 666-676
50. Jiang S, Yu Y, Venners SA et al. Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients. J Hum Hypertens 2011; 25: 172-177
51. Pavarino-Bertelli EC, Sanches de Alvarenga MP, Goloni-Bertollo EM et al. Hyperhomocysteinemia and MTHFR C677T and A1298C polymorphisms are associated with chronic allograft nephropathy in renal transplant recipients. Transplant Proc 2004; 36: 2979-2981 (Pubitemid 41126720)
52. Jamison RL, Shih MC, Humphries DE et al. Effect of the MTHFR C677T and A1298C polymorphisms on survival in patients with advanced CKD and ESRD: a prospective study. Am J Kidney Dis 2009; 53: 779-789
53. Jamison RL, Hartigan P, Kaufman JS et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007; 298: 1163-1170 (Pubitemid 47403102)
54. Eikelboom JW, Lonn E, Genest J Jr et al. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363-375 (Pubitemid 29424631)
55. Antoniades C, Shirodaria C, Leeson P et al. MTHFR 677 C>T Polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothe-lial function in human atherosclerosis. Circulation 2009; 119: 2507-2515
56. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050 (Pubitemid 128753793)
57. Samuelsson O, Lee DM, Attman PO et al. The plasma levels of homocysteine are elevated in moderate renal insufficiency but do not predict the rate of progression. Nephron 1999; 82: 306-311 (Pubitemid 29385302)
58. Menon V, Sarnak MJ, Greene T et al. Relationship between homo-cysteine and mortality in chronic kidney disease. Circulation 2006; 113: 1572-1577 (Pubitemid 43739416)
59. Sandilands AJ, O'Shaughnessy KM. The functional significance of genetic variation within the beta-adrenoceptor. Br J Clin Pharmacol 2005; 60: 235-243 (Pubitemid 41224130)
60. Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 1996; 19: 589-594 (Pubitemid 26315907)
61. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892 (Pubitemid 30419054)
62. Kunz R. Randomized trials and observational studies: still mostly similar results, still crucial differences. J Clin Epidemiol 2008; 61: 207-208
63. Wang X, Lewis J, Appel L et al. Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease. J Am Soc Nephrol 2006; 17: 2900-2909 (Pubitemid 44484681)
64. Fitzmaurice GM, Laird N, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ: Wiley-Interscience, 2004
65. Bostrom MA, Freedman BI. The spectrum of MYH9-associated nephropathy. Clin J Am Soc Nephrol 2010; 5: 1107-1113
66. Genovese G, Friedman DJ, Ross MD et al. Association of trypano-lytic ApoL1 variants with kidney disease in African-Americans. Science 2010; 329: 841-845